cyrilzakka/clinical-trials huggingface dataset:
The Hospital Elder Life Program at the Jewish General Hospital

Older patients (i.e.; ≥ 65 years) with a hip fracture, and who are admitted to orthopedics for surgery are particularly at risk of adverse health events such as delirium, recurrent falls and prolonged hospital stay caused by their frailty status. The Hospital Elder Life Program (HELP) is a comprehensive inpatient-care program that ensures optimal care for older adults in the hospital and, thus, might reduce the incidence of postoperative adverse health events. The overall objective of this study is to examine in a quantitative fashion the effects of the HELP program on adverse health events in geriatric inpatients admitted to the orthopedic ward at JGH for surgery after a hip fracture.

Delirium and mobility impairment with high risk of falls are important medical complications after a hip surgery. More than 95% of hip fractures are caused by falling and the risk of a new fall after a hip surgery may be up to 50%. Both postoperative delirium and fall are associated with increased length of stay and high perioperative mortality.

The Hospital Elder Life Program (HELP) is a comprehensive inpatient-care program that ensures optimal care for older adults in the hospital. The primary goals of the HELP program are:

Maintaining cognitive and physical functioning of high risk older adults throughout hospitalization, maximizing independence at discharge, assisting with the transition from hospital to home, and preventing unplanned hospital readmissions. These goals have been accomplished using a multicomponent intervention strategy. In addition to targeted interdisciplinary geriatric assessment, the program uses an innovative volunteer model to provide personal, supportive attention to vulnerable older inpatients.

Eligibility Criteria:
Inclusion Criteria:

* age 65 and over
* admitted to orthopedic ward for hip surgery after a fracture

Exclusion Criteria:

* younger than 65 years of age
* palliative care
The Added Value of Hybrid Functional Anatomical Imaging PET-CT and SPECT-CT in Patients Treated With Y-90 SIRT for Liver Malignancies

Patients cohort is composed of 50 consecutive patients both male and female with hepatic malignancies, refered to our nuclear medicine department in the process of radioembolization between January 2010- August 2015. 26 of the patients were examined with Tc99-MAA and SPECT-CT and 24 patients were examined with Tc99-MAA , SPECT-CT and PET-CT. Our study protocol was as follows:

1. Collection of anamnestic data
2. Calculation of liver tumor volume with quantification software
3. Evaluation of the liver tumor involvement
4. Evaluation of liver to lung shunt
5. Calculation dose of SIRTEX
6. Y90 imaging
7. Follow Up

The description of the various stages that the patient goes through SIRTex treatment in the department of nuclear medicine and their roll in the study is as following:

The first stage is dedicated to the evaluation of the patient's illegibility for the treatment.

1. In Angiography department
2. In Nuclear medicine department assessment of liver-lung shunting (planar images). Followed by SPECT-CT of the upper abdomen. SPECT with Low dose CT is used to identify a leak to the stomach, duodenum and mesentery, as well as to assess uptake of Tc-99m-MAA in tumor lesions. In order to increase SPECT-CT resolution and sensitivity we co-registrated SPECT-CT with diagnostic CT provided from previous contrast enhanced CT or PET-CT. In this procedure, the Low dose CT is used as bridge between diagnostic CT and the functional imaging SPECT.
3. Calculation dose of Sirtex therapy. At this stage the purpose of the study will be to investigate the added value of SPECT-CT in the estimation of Tc-99m-MAA uptake in tumor lesions.

The second stage is dedicated to the assessment Y-90-SIRTex uptake in liver tumors and to exclude extra hepatic leak. Several hours after treatment patients perform SPECT-CT using Brummshtrullung emission or PET-CT with the peak Zr-90.

At this stage , in our study, we will compare liver lesions uptake of Tc-99m-MAA in the SPECT-CT to lesions uptake of Y-90 -SIRT SPECT/PET-CT as well as to assess if SPECT-CT withTc-99m-MAA may be used as a predictor of Y-90-SIRTex uptake in liver lesion. Does SPECT-CT with Tc-99m-MAA change patient managment.

The third stage of the study is the collection and monitoring of post treatment outcome data.

Eligibility Criteria:
Inclusion Criteria:

* 1. Age ≥ 18. 2. Patients with malignancy of the liver (metastasis or primary tumor) who were treated with Y90 SIRT and were refered to the nuclear medicine department for a PET-CT.

Exclusion Criteria:

* 1. Age \< 18. 2. Pregnant woman 3. Children and legally incompetent.
Supporting Trans Identities and Occupational Justice Through Narrative Informed Theatre: Supporting Trans Identities and Occupational Justice Through Narrative Informed Theatre

Importance: Societal stigma gravely impedes occupational justice for trans individuals, producing vast health disparities for this population.

Objective: Test feasibility and impact of an intervention to reduce stigma and improve trans wellbeing Design: Convergent parallel mixed methods Setting: Community/Webinar Participants: 42 audience members and 6 trans interviewees Intervention: Virtual, narrative-informed play reading and moderated discussion about gender diversity and affirmative care Outcomes and Measures: The valid and reliable Acceptance and Action Questionnaire - Stigma (AAQ-S) assesses stigma beliefs; An open-ended qualitative question assesses trans interviewees' experiences


Eligibility Criteria:
Inclusion Criteria:

* age 18 or older

Exclusion Criteria:

* none
SCN2A Polymorphisms Are Associated With Response to Valproic Acid in Paediatric Population(Pakistan)

The goal of this Observational study was to identify the effect of SCN2A gene polymorphism in the Paediatric epileptic Pakistani population. The main question it aims to answer is:

to evaluate the effect of this genetic polymorphism on the clinical efficacy of Valproic acid

Participants were prescribed Valproic acid after diagnosis of epilepsy.

This observational study aimed to identify the effect of SCN2A rs2304016 gene polymorphism in the Paediatric epileptic population.

The main question it aims to answer is:

• to evaluate the effect of this genetic polymorphism on the clinical efficacy of Valproic acid

The participants' blood samples were taken and further genotyping was performed using conventional tetraARMS PCR. The results were visualized by gel electrophoresis.

Eligibility Criteria:
Inclusion Criteria:

* Epileptic Pakistani individuals of age between 1 to 12 years of either sex
* Each patient had experienced two or more clinically confirmed, spontaneous epileptic seizures in the past.
* Newly diagnosed patients started VPA 20 mg/kg (drug of the same brand was used for every patient throughout the study).

Exclusion Criteria:

* Patients taking any other anti-epileptic drug.
* Patients taking medications that interact with VPA.
* Patients with moderate or severe systemic diseases
Exercise as Adjunctive Treatment for Refractory Epilepsy

The purpose of this research study is to determine whether a 12-week telehealth aerobic exercise intervention is feasible in people with epilepsy.

The study team will also gather information on the effect of the intervention on sleep and stress as mediators of seizure frequency, well as effects on epilepsy and epilepsy associated comorbidities.

This is a randomized, controlled pilot trial to assess the feasibility and fidelity of a 12 week, individualized, telehealth exercise intervention in people with refractory epilepsy. This will be carried out using a 2 arm, parallel group design with a waitlist attention control.

Participants will undergo formal exercise testing prior to enrollment to determine safety and establish a baseline fitness level. Participants will use a wrist-worn Garmin device to record activity and sleep. After a 4 week baseline period, participants will be randomized to intervention or wait-list attention control. The intervention group will undergo a 12-week telehealth exercise program designed by a trained health coach and tailored to the individual's personal fitness level and exercise preferences. The intervention is based in social cognitive theory to implement and enforce sustainable behavior change. The wait-list attention control will receive health education but will not be given an exercise program. At the end of the intervention period, the control group will be given the option to participate in the exercise program.

The study will assess recruitment and retention as well as fidelity, acceptability and sustainability of a telehealth exercise intervention in this population.

The study will investigate objective and subjective measures of the effect of the intervention on the known seizure triggers of sleep and stress as possible mediators of seizure frequency.

The study will collect information regarding the effects of the intervention on depression, anxiety, quality of life, cognition, and seizure frequency.

Eligibility Criteria:
Inclusion Criteria:

* Age 18 or older
* Focal or generalized epilepsy, as clinically determined by a Wake Forest Baptist Health epileptologist.
* Seizure frequency of at least 1 clinically observable seizure in the year prior to enrollment
* Able to ambulate independently without assistive device
* Access to a smartphone with application capabilities
* Internet access or cellular data plan to attend virtual sessions

Exclusion Criteria:

* Diagnosis of nonepileptic or psychogenic spells
* Seizures associated with frequent falls with injury
* \<50% adherence with wearing the device or completing the study diary during the baseline period.
* Currently in an exercise program
* Medical conditions that would limit ability to participate in an exercise intervention such as:
* Stage III or IV Congestive Heart Failure (CHF)
* End-stage Renal Disease
* Severe dementia or significant cognitive impairment
* Uncontrolled hypertension (HTN)
* Motor conditions that limit ambulation
Does Physical Activity Level Depend on Exercise Perception and Body Awareness

Healthy volunteers between the ages of 18-25 who will not have any problems preventing physical activity will be included among the university students. The criteria for not being included in the study were determined as being diagnosed with any disease that impedes physical activity and not wanting to participate in the study. Participation in the investigator's study is completely voluntary. Individuals who do not wish to participate in the study will be excluded. Cases with missing survey and demographic information will be excluded from the study. The planned study is a cross-sectional study.


Eligibility Criteria:
Inclusion Criteria:

* Not having any problems preventing physical activity
* No identified chronic disease
* Being between the ages of 18-25

Exclusion Criteria:

-Not want to participate in the study
A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis

The goal of this open-label clinical trial is to evaluate the efficacy of AzaFol-PET/CT in the diagnosis of GCA (giant cell arteritis), to compare AzaFol- with 2-\[18F\]FDG-PET/CT, and to assess the safety and tolerability of AzaFol in subjects with suspicion of GCA.

Participants will undergo AzaFol-PET/CT imaging at a single timepoint.

Giant cell arteritis (GCA) is the most common systemic vasculitis in the elderly population. 2-\[18F\]Fluor-2-desoxy-D-glucose (2-\[18F\]FDG) positron emission tomography (PET)/ computed tomography (CT) is performed to diagnose GCA (standard of care, SOC) but unable to reliably distinguish atherosclerosis from vasculitis. Activated macrophages express folate receptor (FR)-β and are enriched in inflamed vascular tissue in GCA. 3'-Aza-2'-\[18F\]Fluoro-Folic Acid (AzaFol) is a nuclear tracer targeting FRβ. The investigators hypothesize that AzaFol is a specific and reliable tracer to visualize activated macrophages in GCA and therefore might improve the discrimination of vasculitic and atherosclerotic lesions as compared to 2-\[18F\]FDG-PET/CT.

Eligibility Criteria:
Inclusion Criteria:

* Individuals ≥ 50 years with clinical suspicion of GCA
* Women of childbearing potential must not have a positive serum pregnancy test at the Screening Visit
* Subjects must be able to understand and adhere to all protocol requirements and must voluntarily sign and date an informed consent, approved by an independent ethics committee (IEC)/institutional review board (IRB), prior to the initiation of any screening or study-specific procedures.
* Are willing and able to comply with procedures required in this protocol.

Exclusion Criteria:

1. Folate deficiency
2. Female subjects who are pregnant, breastfeeding, or considering becoming pregnant during the study or within 30 days after the last dose of study drug
3. Concomitant treatment with medications that lead to a significant impairment of folic acid levels (methotrexate, pemetrexed, raltitrexed)
4. Concomitant glucose-containing infusion or parental nutrition within 6 hours prior to 2-\[18F\]FDG tracer application
5. Glucose level \> 10 mmol/l at the timepoint of 2-\[18F\]FDG PET/CT
6. Unable to remain in the PET/CT for the duration of the examination
7. Unable to lie still for the duration of the examination (45 min)
8. Unable not to eat or drink (except water) for 6 hours prior to 2-\[18F\]FDG tracer application
9. Prior PET-imaging within 60 days before baseline
10. Intake of vitamin supplements containing \> 1mg/day folic acid within 48 h prior to the PET/CT with AzaFol
11. Known hypersensitivity or allergy to folic acid
12. Enrolment of the investigator, his/her family members, employees and other dependent persons
13. Participation in another study with investigational drug within the 7 days preceding and during the present study.
The Effect of Konjac Grain in the Post-prandial Glycaemic Response of Healthy Subjects

determine the effect of giving the Konjac-Grain formula as a mixture of white rice in suppressing post-prandial glucose absorption.

To determine the effect of giving the Konjac-Grain formula as a mixture of white rice in suppressing post-prandial glucose absorption.

Benefits of research

1. Scientific benefits Add insight into basic science in the field of metabolic physiology and as a scientific reference in the field of nutrition regarding the benefits of konjac grain in helping to improve blood glucose levels.
2. Practical benefits Providing information, education and knowledge to the public that dietary fiber in the form of konyaku grains is a functional food fiber that has the potential to be useful in improving blood glucose levels.

Length of Research Time:

This research will be carried out for approximately 6 weeks and the treatment will be carried out on the first day of each week. The new treatment was repeated the following week.

Notice of Research Results The blood glucose level examination results will be recorded and given to the test subject on the same day or at the next examination.

Research procedure On the first day of every week the patient will be asked to fast at night for 10-12 hours, then the next day, the subjects are given a ready-to-eat meal treatment with rice mixed with the Konjac-Grain grain formula. After eating, blood glucose levels were measured every 30 minutes for 2 hours. This procedure is repeated weekly with different rice: the Konjac-Grain ratio.

The test subject is asked to sign and write down the date on the consent confirmation sheet to participate as a respondent in this study. The test subject's participation in this research is voluntary. The test subject has the full right to withdraw or cancel participation at anytime. All information on the results of your blood tests is confidential.

The test subject's blood will be collected. This procedure will cause pain in the injection area and blood collection. So far there has never been a report that giving the Konjac-Grain grains or other dietary fiber can cause significant health side effects.

Eligibility Criteria:
Inclusion Criteria:

1. Healthy male or female, aged 18-50 years
2. Not currently taking any medication
3. Do not have a history of metabolic diseases such as hypertension, prediabetes, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) previously from the results of doctor and laboratory examinations.
4. Agree to be included as a research subject (by signing an informed consent)

Exclusion Criteria:

1. Was experiencing an acute infectious disease at the time of the study
2. Lack of sleep or heavy physical activity during the study
3. Subjects experienced pregnancy during the study
4. Subjects withdrew at any time during the research
Improving Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL Weight in ALL)

This study tests the ability of a focused dietary, exercise, and activity intervention to reduce fat gain during induction therapy for childhood acute lymphoblastic leukemia to improve disease response and reduce toxicity.

In our previous study, we have observed that: 1) nearly half ALL patients are overweight or obese at diagnosis, 2) all patients, regardless of starting weight, gain significant fat mass over the first month of therapy (on average 20-30%), and 3) obesity at the time of diagnosis is associated with a higher likelihood of poor response to chemotherapy as evidenced by persistent leukemia (minimal residual disease) after induction therapy. Together, these data show that body fat is a significant risk factor for ALL treatment failure, and that its negative effects are evident within the first month of treatment. Recent laboratory and clinical data illustrates the ability of diet restriction and physical activity to improve chemotherapy efficacy, reduce treatment-related toxicities and better overall quality of life.

Given the importance of successful induction therapy for ALL in predicting long term survival and the negative role of obesity on treatment success, this study tests a complete personalized dietary and exercise intervention for pre-adolescents, adolescents, and young adults newly diagnosed with B-precursor ALL ("pre-B ALL") that aims to reduce fat gained during induction therapy and thereby improve treatment response, toxicity rates, and quality of life.

Eligibility Criteria:
Inclusion Criteria:

* Greater than or equal to 10 years of age and less than or equal to 21 years of age at time of diagnosis
* Have a new diagnosis of untreated NCI/Rome High Risk B-precursor ALL (HR-ALL)
* Are beginning treatment on- or as per- a Children's Cancer Group/Children's Oncology Group (CCG-COG) protocol with a 4-drug Induction including vincristine, daunorubicin (or doxorubicin), asparaginase, and at least 14 days of glucocorticoid steroids

Exclusion Criteria:

* Have a diagnosis of Down syndrome (Trisomy 21) or any genetic disease associated with abnormal body composition
* Be underweight or "at risk for underweight" with moderate weight loss, defined as a starting Body Mass Index (BMI) \<10th percentile for age and sex (for those \>20 years of age, defined as an absolute BMI \< 18.5)
* Have pre-existing abnormal intestinal function (e.g. protein-wasting enteropathy, fat malabsorption)
* Be unable to comply with the recommended diet or activity interventions (as determined by study or treatment team)
* Have a history of prior chemotherapy or radiation for other cancers
* Be unable to complete the necessary radiology examinations with fully interpretable data (e.g. hip replacement and metal prostheses preclude evaluation by DXA)
* Be pregnant (to be confirmed by urine or serum pregnancy test as per institutional routine care for chemotherapy and radiology exams)
Role of Multi-modality Imaging in the Assessment of Chemotherapy Related Cardiac Dysfunction Among Cancer Patients

The field of oncology has advanced remarkably. Some of the old and new emerging cancer therapies are associated with development of cardiovascular toxicities , which may have the potential to offset the gains in survival obtained with this cancer treatment advances. Much of the focus on cardiovascular toxicities has been in the early detection of myocardial damage and prediction of cancer therapeutics-related cardiac dysfunction (CTRCD). The main strategy for these patients is timely diagnosis and treatment of high-risk individual Cardiac dysfunction associated with cancer treatment is the main cause of mortality in cancer survivors. The mortality rate is recorded to be up to 60% in the first two years after therapy. The most commonly associated drugs with cardiotoxicity are anthracycline (AC) and monoclonal antibodies (such as trastuzumab). Other new agents, such as vascular endothelial growth factor (VEGF) inhibitors, immunotherapies, and proteasome inhibitors, can also cause cardiac dysfunction .


Eligibility Criteria:
Inclusion Criteria:

* Cancer patients ≥ 18 years of age, and scheduled to receive chemotherapy will be included.

Exclusion Criteria:

* Contraindications to CMR (e.g.: patients with pacemakers, defibrillators or other implanted electronic devices).
* Life expectancy ≤ 12 months.
* Participating in another oncology clinical trial;
* Prior exposure to chemotherapy;
* History of active or prior cardiac disease (e.g., myocardial infarction, heart failure or base line left ventricular ejection fraction less than 55%).
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

This trial is conducted in Asia, Europe, Middle East, North America, Oceania, and South America.

The purpose of this study is to evaluate the treatment of Recombinant Factor VIIa (eptacog alfa (activated)) in patients with acute intracerebral bleeding. It is expected that more patients will recover without severe permanent disability after acute treatment with Recombinant Factor VIIa by reducing further intracerebral bleeding.


Eligibility Criteria:
Inclusion Criteria:

* Spontaneous intracranial hemorrhage (ICH) within 3 hours after first symptom

Exclusion Criteria:

* Patients with secondary ICH
* Pre-existing disability
* Haemophilia